tiprankstipranks
Trending News
More News >
Hyperfine Inc. (HYPR)
:HYPR
US Market

Hyperfine (HYPR) AI Stock Analysis

Compare
118 Followers

Top Page

HY

Hyperfine

(NASDAQ:HYPR)

Rating:52Neutral
Price Target:
$1.00
▲(28.21%Upside)
Hyperfine's overall stock score reflects a company in transition. Strong revenue growth and a solid equity position are overshadowed by significant profitability challenges and negative cash flows. Technical analysis suggests mixed short-term momentum, while valuation metrics highlight the risks associated with ongoing losses. The earnings call provides some optimism for future growth through diversification and expansion, but the cautious outlook tempers enthusiasm.
Positive Factors
Market Expansion
The sales pipeline is solid, with two new indications (Alzheimer’s, Stroke) set to expand the total addressable market from $1.5 billion to over $6 billion.
Regulatory Approvals
Significant enhancements to imaging quality have been achieved through nine FDA clearances since 2020.
Technology and Innovation
HYPR is partnering with NVIDIA to develop future technologies that incorporate NVIDIA's advanced artificial intelligence (AI) capabilities with the Swoop system.
Negative Factors
Sales and Revenue
HYPR reported Q1 results that missed estimates on the top line, with revenue of $2.1M missing both consensus and estimates by ~$0.7M.
Sales Cycle Challenges
HYPR is seeing an elongation in their selling cycle of up to ~18 months due to ongoing softness in the hospital capital environment.

Hyperfine (HYPR) vs. SPDR S&P 500 ETF (SPY)

Hyperfine Business Overview & Revenue Model

Company DescriptionHyperfine (HYPR) is a pioneering company in the medical technology sector, specializing in the development and commercialization of portable and affordable MRI systems. The company's flagship product, Swoop, is a point-of-care MRI system designed to improve accessibility to MRI imaging by being easy to use and deployable in various medical settings, including emergency departments and rural healthcare facilities.
How the Company Makes MoneyHyperfine generates revenue primarily through the sale and leasing of its Swoop portable MRI systems. The company also earns income from service contracts, offering maintenance and technical support for their equipment. Additional revenue streams may include training services for medical staff and software updates for the MRI systems. Significant partnerships with healthcare providers and research institutions further enhance its market reach and adoption of its innovative MRI technology.

Hyperfine Earnings Call Summary

Earnings Call Date:May 13, 2025
(Q1-2025)
|
% Change Since: 11.43%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call outlines a transitional period for Hyperfine, with significant focus on diversifying revenue streams and technological advancements. While there are promising growth opportunities in the office and international markets, challenges such as prolonged sales cycles, revenue headwinds from grant cancellations, and continued net losses suggest a cautious outlook.
Q1-2025 Updates
Positive Updates
Revenue and Financial Management
Revenue for Q1 2025 was $2.1 million with a strong average selling price. The company raised $6 million through a registered direct offering, extending the cash runway to the end of 2026.
Diversified Growth Strategy
Hyperfine is transitioning from a reliance on U.S. hospital deals to a diversified portfolio including hospitals, office settings, and international markets. The launch of the office business and improved technology are expected to drive growth in the second-half of 2025.
International Expansion
Strong interest and demand are seen across Europe, the Middle East, and Asia, with anticipated regulatory approval and market entrance in India in the second-half of the year.
Technological Advancements
The company is improving the image quality of their AI-powered portable MRI, with expected clearance for next-generation software and technology releases later in the year.
Negative Updates
Revenue Headwinds
Revenue was impacted by the loss of several deals at large academic institutions due to reductions and cancellations of grant funding.
Longer Sales Cycles
Sales cycles for U.S. hospitals are experiencing longer timelines, now estimated to be between 1 to 1.5 years.
Net Loss
Net loss for Q1 2025 was $9.4 million, slightly improved from $9.8 million in the prior year, equating to a net loss of $0.12 per share.
High Cash Burn
Net cash burn for Q1 2025 was $4.6 million, with a total cash burn excluding financing of $10.1 million, although this was down 16% from the previous year.
Company Guidance
During the Hyperfine Q1 2025 earnings call, the company provided guidance on their financial outlook and strategic initiatives. Revenue for the first quarter was reported at $2.1 million, with six systems sold and a strong average selling price. Hyperfine aims to diversify its revenue streams across hospitals, office settings, and international markets, with significant growth expected in the second half of 2025. The company anticipates revenue growth of 10% to 20% over the previous year, with a full-year gross margin outlook of 47% to 50%. Hyperfine also projects a total cash burn of $25 million to $28 million for the year, representing a 31% decline from 2024. The company is focused on expanding the adoption of its AI-powered portable MRI technology, with plans to launch in-office business mid-2025 and has made progress towards international expansion, notably anticipating regulatory approval in India.

Hyperfine Financial Statement Overview

Summary
Hyperfine shows strong revenue growth and a solid equity position with no debt. However, the company faces significant profitability challenges with continuous net losses and negative cash flows. The high equity ratio and lack of debt provide stability, but the negative ROE and cash flow issues indicate a need for improved operational efficiency.
Income Statement
30
Negative
Hyperfine's income statement shows significant revenue growth over the years, with the latest revenue of $12.89 million compared to $0.29 million in 2020. However, the company continues to operate at a loss, with a net loss of $40.72 million for 2024. The gross profit margin has improved to 45.7% in 2024 from a negative margin in earlier years, but net profit margins remain substantially negative. The EBIT and EBITDA margins are also deeply negative, indicating ongoing operational challenges. The revenue growth is a positive sign, but the persistent losses are a major concern.
Balance Sheet
55
Neutral
The balance sheet of Hyperfine shows a relatively strong equity position with stockholders' equity at $49.04 million by the end of 2024. The company has no debt, resulting in a debt-to-equity ratio of 0, which is a positive aspect. However, the return on equity is negative due to significant net losses. The equity ratio stands at 83.2%, indicating a strong capital structure. The absence of debt and a high equity ratio are strengths, yet the negative ROE reflects profitability challenges.
Cash Flow
40
Negative
Hyperfine's cash flow statement reveals negative free cash flow, with a free cash flow of -$39.15 million in 2024. Operating cash flow exceeds net income, suggesting decent cash conversion efficiency, but both metrics are negative. The company has been investing less over time, which may impact future growth prospects. While the company has managed to finance operations without debt, the continuous negative cash flows pose a risk to long-term sustainability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue11.73M12.89M11.03M6.81M1.50M294.00K
Gross Profit5.42M5.89M4.76M907.00K-1.17M-477.00K
EBITDA-42.73M-42.22M-47.06M-72.86M-64.14M-23.20M
Net Income-40.29M-40.72M-44.24M-72.45M-64.83M-23.36M
Balance Sheet
Total Assets53.38M58.90M94.20M134.05M202.47M71.53M
Cash, Cash Equivalents and Short-Term Investments33.09M37.65M75.18M117.47M188.50M62.68M
Total Debt0.00269.00K185.00K0.000.00178.00K
Total Liabilities10.26M9.86M9.80M10.33M16.25M132.58M
Stockholders Equity43.11M49.04M84.40M123.72M186.23M-61.05M
Cash Flow
Free Cash Flow-36.22M-39.15M-42.61M-72.92M-49.89M-23.09M
Operating Cash Flow-35.51M-38.77M-41.81M-72.34M-47.18M-21.52M
Investing Cash Flow-710.00K-383.00K-804.00K-585.00K-2.71M-1.57M
Financing Cash Flow6.55M1.02M174.00K7.00K176.77M60.94M

Hyperfine Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.78
Price Trends
50DMA
0.71
Positive
100DMA
0.78
Positive
200DMA
0.90
Negative
Market Momentum
MACD
0.02
Negative
RSI
56.99
Neutral
STOCH
66.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPR, the sentiment is Positive. The current price of 0.78 is above the 20-day moving average (MA) of 0.74, above the 50-day MA of 0.71, and below the 200-day MA of 0.90, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 56.99 is Neutral, neither overbought nor oversold. The STOCH value of 66.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYPR.

Hyperfine Risk Analysis

Hyperfine disclosed 76 risk factors in its most recent earnings report. Hyperfine reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Hyperfine Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$101.92M-16.53%-4.15%3.49%
60
Neutral
$76.34M-267.29%12.78%15.53%
52
Neutral
$59.55M-67.86%0.34%6.20%
47
Neutral
$37.93M-505.14%-11.21%47.20%
46
Neutral
C$194.90M-3.46-23.22%2.62%21.17%-0.58%
KZKZR
42
Neutral
$33.24M-57.78%-100.00%18.17%
39
Underperform
$45.80M-104.36%-1455.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HYPR
Hyperfine
0.78
-0.26
-25.00%
ICAD
iCAD
3.89
2.60
201.55%
MRSN
Mersana Therapeutics
0.34
-1.69
-83.25%
KZR
Kezar Life Sciences
4.58
-1.68
-26.84%
TELA
TELA Bio
1.96
-2.83
-59.08%
RBOT
Vicarious Surgical
7.72
-1.69
-17.96%

Hyperfine Corporate Events

Executive/Board Changes
Hyperfine Chairperson R. Scott Huennekens Resigns
Neutral
May 23, 2025

On May 21, 2025, R. Scott Huennekens, Chairperson of Hyperfine, Inc.’s Board of Directors, announced his resignation effective May 22, 2025, due to personal reasons and other commitments. His departure was not due to any disagreements with the company. The Board expressed gratitude for his service since 2021 and, in response, reduced its size from six to five members. Daniel J. Wolterman, a current board member, was appointed as the new Chairperson, and the company anticipates his leadership.

The most recent analyst rating on (HYPR) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.

Shareholder Meetings
Hyperfine Holds Annual Stockholders Meeting
Neutral
May 19, 2025

On May 19, 2025, Hyperfine, Inc. held its annual meeting of stockholders, where approximately 90.95% of the voting power was represented. During the meeting, all board nominees were reelected, and Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (HYPR) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 05, 2025